0.609
-0.03 (-4.37%)
| Previous Close | 0.637 |
| Open | 0.643 |
| Volume | 2,605,179 |
| Avg. Volume (3M) | 4,204,995 |
| Market Cap | 75,219,248 |
| Price / Sales | 2.13 |
| Price / Book | 71.71 |
| 52 Weeks Range | |
| Earnings Date | 26 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -214.20% |
| Operating Margin (TTM) | -95.80% |
| Diluted EPS (TTM) | -0.600 |
| Quarterly Revenue Growth (YOY) | 63.70% |
| Total Debt/Equity (MRQ) | 390.80% |
| Current Ratio (MRQ) | 2.72 |
| Operating Cash Flow (TTM) | -132.56 M |
| Levered Free Cash Flow (TTM) | -66.51 M |
| Return on Assets (TTM) | -26.30% |
| Return on Equity (TTM) | -213.33% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Mersana Therapeutics, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | -2.5 |
| Average | 0.17 |
|
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 1.50% |
| % Held by Institutions | 102.30% |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 30 Jan 2025 | Announcement | Mersana Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference |
| 10 Jan 2025 | Announcement | Mersana Therapeutics Announces Additional FDA Fast Track Designation Granted to Emiltatug Ledadotin (XMT-1660) |
| 10 Jan 2025 | Announcement | Mersana Therapeutics Announces Positive Initial Clinical Data from Phase 1 Clinical Trial of Emiltatug Ledadotin (XMT-1660); Initiation of Expansion in Triple Negative Breast Cancer |
| 13 Nov 2024 | Announcement | Mersana Therapeutics Provides Business Update and Announces Third Quarter 2024 Financial Results |
| 06 Nov 2024 | Announcement | Mersana Therapeutics to Host Third Quarter 2024 Conference Call on November 13, 2024 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |